Try GOLD - Free
We train professionals to see quality not as a checklist but as a mindset
Express Pharma
|January 2026
Prof. Dr Syed S. Abbas, Director, Institute of Good Manufacturing Practices India (IGMPI), explains how globally benchmarked programmes, hands-on learning, industry-aligned curricula, and flexible training models are preparing professionals to meet global compliance expectations and strengthen India's position as a hub for safe, high-quality pharma products, in an interaction with Kalyani Sharma
-
How does IGMPI's training ecosystem directly address the root causes of patient-safety lapses such as weak documentation, manufacturing deviations, and gaps in pharmacovigilance within India's pharma and healthcare sectors?
If we look closely, most patient-safety failures don't happen overnight. They start small, maybe a missed entry in a logbook, a deviation that isn't fully documented, or a followup on an adverse reaction that's delayed. At IGMPI, our programmes are designed around addressing exactly these weak points.
We train professionals to see quality not as a checklist but as a mindset. Modules on good documentation practices, data integrity, deviation handling, and CAPA make participants understand why precision matters at every step. Similarly, our pharmacovigilance courses build the skills needed to monitor drugs even after they're out in the market, ensuring that any risk is caught early. When professionals learn to connect each step of compliance with the larger picture of patient safety, they make fewer mistakes and when they do, they know how to respond effectively. That's the culture we try to build through our training ecosystem.
IGMPI's programmes are benchmarked to USFDA, EMA, WHO, and ICH guidelines. Could you elaborate on how aligning with these global standards helps Indian professionals meet international compliance expectations and support India's export readiness?
This story is from the January 2026 edition of Express Pharma.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM Express Pharma
Express Pharma
Future opportunities in biologics and biosimilars will demand significant investment
Semaglutide's patent expiry in India in March 2026 has become the immediate trigger for the next wave of pharmaceutical development activity, but the larger opportunity goes well beyond semaglutide itself.
1 mins
April 2026
Express Pharma
Gandhi Automations elevates loading bay efficiency with advanced dock leveler solutions
Engineered systems from Gandhi Automations Pvt Ltd enhance safety, durability and seamless material flow
2 mins
April 2026
Express Pharma
Redefining humidity control in pharma manufacturing
Bry-Air systems reflect shift towards material-based humidity control in pharma manufacturing
2 mins
April 2026
Express Pharma
2026 amendments to NDCT Rules: Foreword to India's biosimilars story or a step too short?
Kosturi Ghosh, Partner, and Ajeya B G, Sr Associate, in the Corporate practice at Trilegal, assess India's 2026 NDCT amendments as a timely push for biosimilars, but not enough on their own. The article highlights that stronger policy clarity and ecosystem support will be critical to truly unlock growth.
4 mins
April 2026
Express Pharma
Optima advances digital twins to boost efficiency in pharmaceutical turnkey machines
Virtual testing, training and simulation tools enhance performance in complex manufacturing environments
7 mins
April 2026
Express Pharma
Complete environmental monitoring solution – testo Saveris Pharma
There are several critical applications in the industry like research and development that demand for continuous & reliable monitoring of important environmental parameters.
3 mins
April 2026
Express Pharma
Flexotherm heating tapes & cords
Typical Applications of Heating Tapes and Cords in Industrial Solvent Handling
1 mins
April 2026
Express Pharma
Safeguarding the pharma excipients supply chain
Adding excipient details to QR codes of the top 300 drugs may not be a tough task. But as CDSCO plans to expand QR codes to cover other critical drug categories in phases, all segments of the pharma value chain need to tighten their systems, analyses Viveka Roychowdhury
15 mins
April 2026
Express Pharma
This is only the beginning of a much larger global patent-cliff cycle
As the patent expiry of semaglutide is almost there in India, several Indian pharma firms are preparing to introduce generic versions, highlighting the sector's agility in responding to high-value loss-of-exclusivity opportunities.
1 min
April 2026
Express Pharma
Leading people in the age of Al
As Al reshapes pharma, HR leadership is being drawn into a deeper question that goes beyond technology to the future of people and work, finds Lakshmipriya Nair
8 mins
April 2026
Listen
Translate
Change font size

